Weekly Rundown
| 4 min read
The Bethesda Declaration, a new RSV antibody for kids, amylin’s promising weight loss results, and more were industry’s need-to-know stories this week.
| 5 min read
Promising small cell lung cancer results, COVID-19 vaccine confusion, billion-dollar deals, and more led the news this week.
| 4 min read
HHS decisions on COVID-19 and flu vaccines, new therapies with encouraging results for depression and ALS, and more industry news this week.
| 5 min read
From a bladder transplant to a blood test for Alzheimer's disease, there were a lot of firsts this week. Check them out here along with more industry news.
| 5 min read
From an executive order to lower drug prices to GLP-1 drug comparisons and a link between Parkinson’s disease and golf courses, it was a busy industry news week.
| 4 min read
An executive order on drug manufacturing, a controversial HHS appointee, a diabetes drug for prostate cancers, and more were this week’s top industry headlines.
| 5 min read
Highlights from AACR 2025, COVID-19 vaccine flip flops, an FDA approval for a rare skin disorder, and more led biotech and pharma news this week.
| 4 min read
Landmark women’s health study loses funding, a promising antibody-drug conjugate for breast cancer, a schizophrenia drug setback, and more news from this week.
| 5 min read
Stem cell therapy for Parkinson’s disease, discontinuation of Pfizer’s GLP-1 drug, a pig liver clinical trial, and more biotech and pharma news from this week.
| 5 min read
Insights from the AD/PD meeting, continued fallout from the FDA layoffs, hope for GLP-1 drugs in Alzheimer’s disease, and more led industry news this week.
Page 1 of 2 - 14 Total Items
